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Abstract 
Background. Cancer of the larynx in the intermediate/advance stage still presents a major 
challenge in terms of controlling the disease and preserving the organ. Among therapeutic 
options, open partial horizontal laryngectomy (OPHL) is proposed as function-sparing 
surgical technique.  
Methods. We analyzed the clinical outcomes of 555 patients with laryngeal cancer staged 
pT3–pT4a who underwent OPHL.  
Results. 5 years overall survival, disease-free survival, locoregional control, local control, 
laryngectomy-free survival and laryngeal function preservation rates were 84.6%, 84.2%, 
86.3%, 90.6%, 93.3% and 91.2%, respectively. Disease-free survival, locoregional control 
and laryngeal function preservation prevalences were significantly affected by pT4a 
staging (68.1%, 71.7% and 78.0% respectively), while pN+ influenced only disease-free 
survival (≤72.6%) and locoregional control (≤79.6%).   
Conclusions. in cases of laryngeal tumors at intermediate and selected advanced stage, 
also with sub-glottic extension, the choice of OPHL with a modular approach can be 
considered effective in terms of  prognostic and functional results. 
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Introduction 
The first and basic common step in curing laryngeal squamous cell carcinoma (SCC) is 
assessment of the type, extent and pattern of the neoplasm. The second step is choice of 
treatment that should be as conservative as possible, above all for surgical approaches. In 
fact, after the first total laryngectomy performed by Prof. Theodor Billroth on 31 December 
1873,1 the problems of voice preservation and airway restoration spurred surgeons 
towards the development of organ/function sparing, though oncologically sound, 
procedures. Nowadays their employment represents the common trend among therapeutic 
approaches,2-4 having significantly increased the survival from laryngeal SCC, although 
poor prognosis and loss of larynx functionality are still common features of the disease, 
especially in its advanced stage. Generally, open neck demolitive or “partial functional 
laryngectomies” represents the surgical procedure of choice, the greater part of which, 
above all in Europe, is represented by open partial horizontal laryngectomies (OPHL). 
Literature addressing this topic is rich, and a number of surgical procedures have been 
described coping with the different patterns of endolaryngeal tumor site and spread.5-9 
Recently, the European Laryngological Society proposed a classification of the more 
commonly adopted procedures according to extent of resection,10 including three types of 
OPHL: Type I - supraglottic, Type II - supracricoid and Type III - supratracheal. The latter, 
described in 2006, is based on resection of the entire glottic and subglottic sites and of the 
thyroid cartilage, sparing both or at least one functioning cricoarytenoid unit.11 In our 
practice, extending the limits of resection, OPHL Type III enlarges the indications 
suggested by National Comprehensive Cancer Network (NCCN) and Italian Head and 
Neck Society (IHNS) guidelines for the treatment of laryngeal cancer with conservative 
surgery (T1-T2, N0 or selected T3): some problematic glottic cT3 (i.e. sub-glottic extension 
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and cricoarytenoid joint invasion) and some supraglottic cT3 (i.e. large transglottic 
extension) became now manageable by OPHL, showing promising oncological and 
functional results.12, 13 Even, albeit with great caution, the same practice can be considered 
as up-front option in very restricted cT4a cases, with minimal anterior extralaryngeal 
extension, when it is reasonable to expect an exclusive treatment.  
In this study, we present a multicentric retrospective outcome analysis of 555 patients with 
supraglottic/glottic laryngeal SCC in the intermediate/advanced stage, managed by OPHL 
type II or III. The analysis was conducted over a 16-year period, during which organ-
preservation protocols with chemoradiotherapy or total laryngectomy were applied as 
conventional therapeutic options for these types of locally advanced tumors.2, 4 
 
 
 
Material and Methods 
Patients 
All patients were from the Hospital of Vittorio Veneto, Treviso, or the Martini Hospital of 
Turin. Selection was based on routinely performed clinical assessment lasting 3 weeks 
prior surgery, in order to evaluate the superficial and depth extent of the tumor, as 
previously described.12 
Inclusion criteria were histological diagnosis of intermediate/advance stage glottic or 
supraglottic laryngeal SCC, with Karnofsky index14 higher than 80. 
Exclusion criteria were severe diabetes mellitus, severe bronchopulmonary chronic 
obstructive disease, neurological problems impairing the ability to expectorate and/or 
swallow, or severe cardiac disease. Advanced age, an important cut-off for relative 
surgical indication,15 has not been considered, in itself, an exclusion criterion.  
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Surgery 
After informed consent had been obtained, 555 patients were selected to undergo a 
modular function sparing surgical approach from January 1, 1995 and December 31, 2011. 
Ninety-six patients (17.2%) included in the present analysis had been treated previously 
for laryngeal carcinoma by CO2 transoral laser surgery (38 of 96; 39.5%), (chemo)-
radiation therapy (35 of 96; 36.4%), open partial laryngectomy (8 of 96; 8.3%) or 
cordectomy (15 of 96; 15.6%). 
The tumors were glottic in 506 patients and supraglottic in 49 patients. The vocal fold 
mobility was: 30 cases with normal or impaired vocal cord mobility (19 supraglottic pT3 
and 11 supraglottic pT4a), 443 cases with fixed vocal cord and mobile cricoarytenoid joint 
(15 supraglottic pT3, 4 supraglottic pT4a, 152 transglottic pT3, 207 glottic pT3, and 65 
glottic pT4a) and 82 cases with fixed vocal cord and cricoarytenoid joint (48 glottic-
subglottic pT3, 33 glottic pT4a, and 1 transglottic pT3). 
Resections were classified according to the European Laryngological Society 
Classification.10 In particular, only Type II and III OPHLs were performed: Type IIa 
(supracricoid partial laringectomy/crico-hyoido-epiglottopexy) = 62 (11.1%), Type IIa + 
ARY = 243 (43.8%), Type IIb (supracricoid partial laringectomy/crico-hyoido-pexy) = 32 
(5.8%), Type IIb + ARY = 117 (21,1%), Type IIIa (supratracheal partial 
laryngectomy/tracheo-hyoido-epiglottopexy) = 9 (1.6%), Type IIIa + CAU = 82 (14.8%), 
Type IIIb (supratracheal partial laryngectomy/tracheo-hyoido-pexy) = 4 (0.7%), Type IIIb + 
CAU = 6 (1.1%), where “+ARY” represents the removal of one arytenoid and “+CAU” the 
removal of one cricoarytenoid unit. 
The indications adopted for Type II (a+b) OPHLs were the classical ones, applied 
according to tumor extent, now being accepted and advocated by numerous authors.6, 7, 9, 
16  
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Although definitions for the Type III (a+b) OPHLs were only recently introduced, the 
precise indications and contraindications adopted were those already described in our 
previous study for tumors in the intermediate/selected T classification.12 Anyway, a further 
contraindications to Type III (a+b) OPHLs and related to locoregional extent was 
supraglottic T4a tumors reaching the base of the tongue or invading the hyoid bone. 
In all patients, resection margins were examined intraoperatively with frozen sections: 
when positive, the resection was expanded until the margins were negative. As the 
interventions were conducted using the principles of a modular approach, the resection is 
always prepared in standard mode and the larynx is opened from the side less affected by 
disease. At this point, under visual control, the subsites involved are removed and the 
resection can be easily enlarged as follows: (1) Type IIa/b  Type IIa/b + ARY; (2) Type 
IIIa/b  Type IIIa/b + CAU; (3) Type IIa  Type IIb; (4) Type IIa/b + ARY  Type IIIa/b + 
CAU; (5) Type IIIa  Type IIIb. 
The margins of the surgical specimen were always checked again upon definitive 
pathology. Neck dissection (ND), graded according to the American Academy of 
Otolaryngology - Head and Neck Surgery Foundation classification,17 was performed in 
503 patients (90.6%), and was monolateral in 324 (64.4%) and bilateral in 179 (35.6%) 
cases. ND was elective (ND levels II-IV) in 447 cN0 patients (88.9%) and curative (ND 
levels II-V + Internal Jugular Vein in one case) in 56 cN>0 patients (11.1%). In 123 
patients, whole level VI or unilateral paratracheal lymph node clearance was added. No 
ND was performed in an additional 52 patients (9.4%) (elderly and/or cN0 disease or in 
previously treated neck). 
 
Postoperative care and adjuvant treatments 
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All patients were monitored for early complications (local and general) and late sequelae. 
Patients underwent the same rehabilitation protocol, apart from those with serious early 
complications. 
The postoperative protocol was in accord with our previous report.12 Briefly: (1) insertion of 
an uncuffed tracheal cannula and beginning of phonation (days 1 to 4); (2) intermittent 
occlusion of the tracheostomy with saline-soaked gauze and starting of feeding without the 
tracheal cannula in position (days 4 to 6); (3),nasogastric (NG) tube removal as soon as a 
good level of swallowing of both solids and liquids was achieved (day 6 onwards). Post-
operative aspiration was graded in accordance with Pearson’s scale.18 On the basis of 
pathological findings (pN+ and/or extracapsular spread, large extralaryngeal extent, 
positive margins), 72 patients (12.9%) were subjected to adjuvant radiotherapy. The 
indications for adjuvant therapy were: 40 N+ (14 level VI pN+, 26 pN2), 27 cases with 
gross extralaryngeal extent (3 supraglottic pT4a and 24 glottic pT4a) and 5 cases with 
positive margins. 
A large volume encompassing the primary site and all draining lymph nodes was irradiated 
with a dose of up to 54 Gy/2 Gy. Regions at higher risk for malignant dissemination 
received a 12-Gy boost (total 66 Gy/2 Gy – range 62–68 Gy). Forty-two of 72 patients also 
received 100 mg/m2 cisplatin on days 1, 22, and 43 of the course of radiotherapy.19 
 
Larynx functional assessment 
Pearson’s scale evaluation was repeated and larynx functional status was evaluated with 
the Performance Status Scale throughout five post-operative years.20 
 
Statistical methods 
Overall survival (OS), disease free survival (DFS), disease specific survival (DSS), 
locoregional control (LRC), local control (LC), laryngectomy free survival (LFS) and 
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laryngeal function preservation (LFP), were assessed by means of Kaplan-Meier curves. 
Log-rank and Gehan-Breslow-Wilcoxon tests (for early events) were used to compare 
Kaplan-Meier estimates between groups (staging, clinical history of previous treatment, 
type of surgery, and age).  The end points considered were obtained as the length of time 
from the date of diagnosis to: OS) the date of death; DFS) the date of the first recurrence; 
DSS) the date of death from the disease; LRC) the date of the first locoregional 
recurrence; LC) the date of the first local recurrence; LFS) the date of total laryngectomy; 
LFP) the date of total laryngectomy or presence of tracheostomy, NG tube, gastrostomy 
feeding, or non-intelligible voice.  
All analyses were performed with GraphPad Prism version 5.00 (GraphPad Software, San 
Diego CA), with p < .05 as the significant cutoff. 
 
Results 
 
Patients 
A cohort of 555 patients undergoing Type II or III OPHLs was considered (Table 1). 
Current or former smokers made up 93% of the cohort. Patients were followed for a mean 
period of 5.57 years.  
 
Pathology 
All patients suffered of a biopsy-proven supraglottic or glottic laryngeal SCC, which it was 
classified as pT3 or pT4a, according to the 2002 TNM classification system21 (Table 1). 
Furthermore, pathology reports indicated close margins (<2 mm) in 13 cases (2.3%) and 
positive margins at the definitive histopathologic examination in 5 cases (0.9%). Four 
hundreds ninety-nine patients (89.9%) had been staged as cN0 by palpation and neck CT-
scan or MRI. Overall, lymph node metastases were detected in 71/555 patients (12.8%), of 
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whom 40 (7.2%) had multiple metastases. Furthermore, the comparison between clinical 
and pathological staging showed up-staging of the primary tumor in 83 cases (14.9 %) and 
of the lymph nodes in 15 cases (2.7%). 
 
Survival and disease control 
The 5-year OS, DSS, DFS, LRC and LC were 84.6%, 92.8%, 84.2%, 86.3% and 90.6%, 
respectively (Figure 1). At the last follow-up, a total of 89 patients died, 39 of them from the 
cancer under study and 50 for causes unrelated to laryngeal cancer (Table 2). 
 
Chart data stratification 
Locally intermediate/advanced laryngeal carcinomas differ greatly in surgical indications 
and prognosis. The analyses were hence conducted on the basis of pathological staging in 
order to obtain homogeneous prognostic data. By stratifying the chart data, we evaluated 
whether pT, pN and type of surgery could affect the OS, DFS and LRC end-points in terms 
of prevalence (Figure 2).  
After 5 years from surgery, OS was greatly affected by pT and pN classifications. In fact, it 
was 87.8% and 71.2% in pT3 and pT4a patients, respectively, whereas it is only 51.5% in 
pN≥2 patients, although similar in pN0 (88.3%) and pN1 (88.5%). Also the choice of more 
extensive surgery (OPHL Type III) can affect OS (87.7%, 84.6%, 74.3% and 72.0% for 
patients underwent Type IIa, Type IIb, Type IIIa and Type IIIb OPHL surgery, respectively). 
Anyway no significant differences can be detected considering the DSS end-point (from 
94.6% of OPHL Type IIb to 87.6% of OPHL Type IIIa, p = .242). 
DFS prevalence was greatly affected by locoregional staging and surgical approach. In 
fact pT4a patients had 68.1% DFS if compared with 87.9% of those classified as pT3; 
similarly also pN+ patients (72.6% pN1 and 71.1% pN≥2) had worse outcome with respect 
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to pN0 (88.2%). As consequence, Type III OPHL (66.6% IIIa, 70.0% IIIb) were less 
effective than Type II (85.1% IIa, 91.8% IIb) in maintaining patients free from disease. 
The same pattern was also evident for the LRC end-point: 71.7% pT4a vs 89.7% pT3; 
72.0% pN1 and 79.6% pN≥2 vs 89.8% pN0; 72.1% OPHL Type IIIa and 70.0% IIIb vs 
87.6% Type IIa and 92.5% IIb.      
We assessed also the impact of eventual previous treatment and age ≥65 without 
retrieving any significant differences (data not shown).  
 
Patterns of failure 
Locoregional recurrences affected 66 patients within 5 years of surgery. According to the 
site of pathology, they were sub-grouped as 40 local (60.6%), 5 locoregional (7.6%) and 
21 regional (31.8%) recurrences. 
Local recurrences were observed in 35/459 (7.6%) untreated and 10/96 (10.4%) pre-
treated patients. Among them, eight had inferior paraglottic space involvement, 4 had 
internal thyroid lamina involvement, 10 had transglottic extension, 3 had subglottic 
extension and inclusion of a cricoarytenoid joint, 2 had surface extension as far as the 
inferior edge of the cricoid ring, 15 had extralaryngeal extension (9 anterior, 6 posterior) 
and 3 showed surface extension toward the posterior commissure. 
In all patients with local recurrence, salvage therapy included total laryngectomy and 
adjuvant radiation therapy and/or chemotherapy in 29 patients, radiation therapy and/or 
chemotherapy in eleven patients and laser surgery in five cases. Totally, seventeen 
patients died of laryngeal cancer from progression of disease (average 18.1 months, range 
3–42 months), 7 patients died of other disease, while at the last follow-up, 1 patient was 
alive with the disease and 20 patients were alive and disease-free; overall local control 
after salvage therapy at 5 years, was achieved in 27 of 45 patients (60.0%).  
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Recurrence in the neck was observed in 26 cases, 19 of whom were previously classified 
as cN0 and 7 as cN>0 patients. At the time of primary resection, 2 of these 26 received 
unilateral neck dissection, 14 received bilateral neck dissection, and eight out of 26 
recurrences were observed at the VI level. 
Four recurrences in the neck were treated with surgery alone, twenty with surgery and 
adjuvant radiation therapy and/or chemotherapy, two recurrences with chemotherapy. 11 
patients died due to regional recurrences (range 6–38 months, mean 16.3 months), 2 
patients died of other disease while at the last follow-up, 3 patients were alive with disease 
and 10 patients were alive and disease-free. 
 
Postoperative course and morbidity 
Overall, acute complications during hospitalization occurred in 62 out 555 patients (11.2%) 
and there were 3 perioperative deaths. The mean hospitalization time for patients with 
acute complications was 32 ± 6 days, which was significantly longer than that for patients 
without acute complications (21 ± 5 days). Late sequelae following discharge were 
observed in 85 out of 555 cases (15.3%) (Table 3). All were successfully treated with 
transoral CO2 laser surgery (68/85, 80%), revision of the pexy (2/85, 2.3%), injective 
laryngoplasty using Vox-implants, which successfully treated dysphagia (5/85, 5.8%), 
completion laryngectomy (5/85, 5.8%), or other endoscopic procedures (5/85, 5.8%). 
 
Laryngeal function preservation 
At 5 years after surgery, LFP rate was 92.6% (514 out 555 patients) while LFS resulted 
93.3% (524 out 555 patients) (Figure 3). In addition, we evaluated whether LFP could be 
affected by local or regional staging, presence of previous treatment, or age ≥65 years 
(Figure 4). Patients affected by advanced pT stage were statistically significantly more 
prone to lose laryngeal function (78.0%) with respect to intermediate pT stage (94.2%). 
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Otherwise, pN was not correlated with LFP: in fact, differences between pN0 (94.1%) and 
pN>0 (86.3% pN1 and 86.9% pN≥2) were not significant. LFP is affected by surgery 
(proportionally to the extent of resection) and by age, but only limited by the first years 
after the surgery. Although log rank test did not provide significant results in the 
comparison between younger (92.6%) and older (88.5%) patients, we can appreciate a 
significant difference at early times employing the Gehan-Breslow-Wilcoxon test. Finally, 
LFP was not biased by previous treatments (not shown).  
After the first post-operative month, normal swallowing (Pearson’s scale Grade 0) was 
achieved in 333 patients (60.0%), Grade I and II were observed in 115 (20.7%) and 91 
(16.4%) patients, respectively, while aspiration pneumonia (AP) (Pearson’s Grade III) was 
recorded in 16 patients (2.9%). After the second year, a satisfactory degree of laryngeal 
function (i.e. List’s scale: eating in public >50, understandability of speech >50, Normalcy 
of diet >70) was achieved in 460 out of 555 patients without local disease (82.9%). Out of 
the 528 patients evaluated for subjective aspiration by the Pearson’s scale, 227 (43%) had 
no aspiration (Grade 0), 231 (43.8%) had occasional cough without clinical problems 
(Grade I), 62 (11.7%) had constant cough that worsened during meals (Grade II), and 8 
patients (1.4%) had frequent pulmonary complications (Grade III). Nearly all patients 
(547/555; 98.6%) had the NGT or gastrostomy removed. The NGT remained in place for 
an average of 19.5 days (range 11–161 days). 
Overall, AP was observed in 41/555 cases (7.4%), 16 cases during hospitalization and 25 
cases during follow-up, which required a temporary gastrostomy; for 30 of them, it was 
removed within the first post-operative year. In 14 cases, the gastrostomy was maintained 
due to repeated episodes of AP and severe dysphagia for liquids. In seven cases, total 
laryngectomy was proposed for persistent aspiration: five patients accepted this treatment 
while two refused, preferring to keep the gastrostomy and maintain voice. Five patients 
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were subjected to the endoscopic procedure for injective laryngoplasty using Vox implant, 
which successfully resolved the dysphagia, allowing gastrostomy removal. 
The mean time to intermittent occlusion of the tracheostomy was 24.6 days (range 3–406 
days), and the average time to tracheostomy closure was 82.4 days (range 23–489 days). 
In our protocol, progressive closure of the tracheostomy is preferred, and occurs 
spontaneously in the majority of patients following occlusion. For patients, especially in the 
first weeks after discharge, this leads to a sensation of greater safety concerning minor 
episodes of food inhalation, which are relatively frequent. When the tracheostomy has 
almost closed, minor plastic surgery can then be performed. 
 
 
 
 
 
 
 
Discussion  
 
Notwithstanding that the preservation of laryngeal function is one of the major advances 
that have been achieved over the past decades, cancer of the larynx in the 
intermediate/advance stage still presents a major challenge in terms of controlling the 
disease and preserving the larynx, regardless of the therapeutic option chosen.2-4, 6, 7, 9, 22-
25 In fact, many glottic cT3 tumors with sub-glottic extent (vocal cord and arytenoid fixation) 
often result in early pT4a for extralaryngeal extent, making them of difficult management 
with chemoradiotherapy or supracricoid laryngectomy. 
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Towards the end of the 1990s, by analyzing total laryngectomy and supracricoid 
laryngectomy specimens, in comparison with clinical data from fixed arytenoid and 
subglottic swelling, the idea of extending the supracricoid laryngectomy downwards to 
obtain safer margins was derived. These efforts have resulted in increased knowledge, 
which led to the proposal of a new type of OPHL in 2006, the supratracheal laryngectomy, 
otherwise known as OPHL Type III in the recent European Laryngological Society 
classification.10 As recently demonstrated by Schindler et al. and Rizzotto et al., this is able 
to spare laryngeal function without compromising locoregional control during long-term 
follow-up.12, 13 As a consequence of the diffusion of supracricoid partial laryngectomies 
(OPHL Type II), the advent of supratracheal partial laryngectomies (OPHL Type III) and 
the consolidated role of conventional non-surgical organ sparing protocols, the role of total 
laryngectomy in the treatment of endolaryngeal neoplasms has decreased considerably. 
In this study, we have analyzed the outcomes of 555 patients affected by III-IV staged 
laryngeal SCC undergoing function sparing OPHL protocols. For the sake of clarity, we 
report in our cohort an higher percentage of glottic tumors (91.2%) than in previously 
described trials or case series for the great number of transglottic cancers (27.4%), which 
were included and being these always considered to originate from the glottis. 
During the surgery, the open partial resection was tailored under visual control to obtain 
disease-free safe margins, which can be as close as of only 4–5 mm. It is important to 
note that such intra-surgery flexibility can be useful to address the heterogeneity of tumors 
on the base of their true extent. In our series, in fact, upstaging of cT3 to pT4a was found 
in 14.9% of specimens, generally due to the full thickness involvement of the thyroid 
lamina, and of cN0 to pN+ in 3% of cases, in spite of preoperative neck CT and/or MRI. 
Being aware of these, otherwise not identifiable, upstaging may represent an explanation 
of the differences we already reported12 and here further confirmed, in terms of local 
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control between concomitant chemoradiation and OPHLs in the management of laryngeal 
cancer at the intermediate stage. 
In fact, data concerning survival and disease control do not display significant differences 
with respect to our previous analysis,12 but highlighted great differences with literature data 
concerning non-surgical approaches. In the present study, the 5-year OS was 84.6% and 
results better than what previously reported for both concomitant chemoradiotherapy or 
induction chemotherapy and radiotherapy (~60%).4, 26  More advanced pT4a tumors 
displayed a 5-year DFS of 68.1%, a result in line with that of the most demolitive surgical 
approach, although it must be admitted that in these cases the extralaryngeal extension 
was minimal. These data show that a careful selection can render eligible for the partial 
modular surgical approach a good number of patients, even in some, very well selected 
“extreme cases”. However, the DFS for pT4a cancer (68.2%) was significantly lower than 
that for pT3 classification (87.9%), but higher than that obtained by management with 
radiotherapy and/or chemoradiotherapy, which ranged from 26% to 38%, respectively.4, 26. 
Finally, the number of patients which were subjected to total laryngectomy for either 
functional or oncological purposes was significantly low (6.2%) and there were only three 
perioperative deaths. The high laryngectomy-free survival rate here achieved deposed to 
the great potentiality of OPHL approaches in preserving the larynx. In summary, 
“everybody loses a piece, but few lose all”. 
Otherwise, larynx function preservation takes great advantages by tailoring surgery on the 
real extent of tumor, and significant differences (p < .001) are found after 5 years from 
surgery between OPHL type II (94.4%) and Type III (74.5%) patients. Here is important to 
note that the latter is consistent with our previous report (78.5%),12 which was itself in line 
with that achievable with concomitant chemoradiation. As a consequence, maintenance of 
laryngeal function was more critical in patients affected by pT4a cancer (78.0%) and in 
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those older than 65 (87.3%), although only if we consider early events as more severe 
than late ones.  
The real Achilles heel of OPHLs is represented by a greater proportion of functional 
problems compared to non-surgical treatment options. As already reported by Benito et 
al.,27 persistent slight dysphagia and aspiration pneumonia still represent major 
complications in patients undergoing OPHLs, especially Type III, while voice was 
significantly deteriorated, and generally quite hoarse and breathy.13 Despite the 
employment of the less extended OPHL Type II, no differences in terms of acute 
complication and late sequelae were highlighted with respect to our previous analysis.12 In 
fact, 19 out of 41 cases of aspiration pneumonia occurred in elderly patients, in whom 
gastrostomy was maintained in two patients owing to repeated episodes of aspiration 
pneumonia, and one was subjected to total laryngectomy. Fortunately these phenomena 
are not frequent, tend to self-restraint and to be well tolerated by patients. On the other 
hand, a significant reduction (p < .01) in hospitalization time can be achieved by better 
tailoring the surgery on tumor extent. Indeed it is here reported a mean hospitalization of 
32 and 21 days in presence or without acute complications, respectively, which were 
opposed to the 38 and 24 days achieved by Rizzotto et al. employing only OPHL Type III 
procedure.12  
Aiming these surgical options at carefully selected patients suffering from laryngeal SCC in 
well-defined intermediate/advanced stages, the oncological and functional results are very 
robust and repeatable. Many experiences reported in the past 20 years supports this 
claim.5-9 The gold standard indications are: supraglottic cT3 (OPHL Type IIb ± ARY), glottic 
cT3 with vocal cord fixation (OPHL Type IIa ± ARY), glottic cT3 with vocal cord fixation ± 
arytenoid fixation and also sub-glottic extension (OPHL Type IIIa ± CAU). In the latter case 
the option of a supracricoid partial laryngectomy would be very much at risk of leaving 
positive margins as the section line passes through a cricoarytenoid joint. A different and 
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more cautious reasoning is required for anterior cT4a tumors with full-thickness 
involvement of the thyroid lamina and/or minimal extralaryngeal extension: by adopting 
OPHL, the radicality is the same as for the more demolitive interventions, but the selection 
of patients must be made very carefully because, at the end of the work-up, the surgeon 
must be able to ensure safe margins with sufficient certainty, thus avoiding an upfront total 
laryngectomy. 
In all cases in which the extent of the tumor determines the indication for a more extreme 
Type III partial laryngectomy (and this occurs for most tumors with sub-glottic extension or 
extension towards the posterior commissure), this imposes a serious ethical consideration. 
In fact, in many specialized centers, these cases are considered to be "amenable with total 
laryngectomy" and therefore, up-front directed to non-surgical treatment in order to spare 
the larynx. When discussing a conservative surgical option with the patient, it must be 
explained clearly that if the resection margins are positive in frozen sections, the option 
immediately following that is total laryngectomy, thus "jumping" the option of concomitant 
chemoradiotherapy, which has a degree of recommendation IA. For these reasons, 
especially when the tumor clearly extends beyond the limits of the larynx, both the severity 
of the intervention and the necessity for adjuvant radiotherapy demand that extreme 
caution be taken when considering the indications. 
In conclusion, here we demonstrate that, in cases of supraglottic tumors with glottic 
involvement, any subtype of glottic cT3 and finally some well-studied glottic tumors with 
sub-glottic extension, the choice of OPHL with a modular approach versus chemoradiation 
protocols can be considered to be viable not only in prognostic terms (above all for the 
possibility to identify upstaging and the reduction in recurrence prevalence) but also in 
terms of functional results (similar of what obtained by non-surgical options) such as a 
reduction of total laryngectomies, even at the expense of voice quality and rare 
occurrences of sequelae (aspiration pneumonia).  
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Figure legends 
Fig. 1. End point analysis (overall survival, disease specific survival, disease-free survival, 
locoregional control, and local control) of the patient cohort using Kaplan–Meier curves. 
 
Fig. 2. Patient cohort stratification for pT classification (left column), pN classification 
(middle column) and type of surgery (right column) using Kaplan–Meier curves. The end 
points considered were (from top to bottom) overall survival, disease-free survival, loco-
regional control, and local control. * = p < .05; ** = p < .01; *** = p < .001 
 
Fig.3. End point analysis of laryngeal function preservation and laryngectomy-free survival 
in the patient cohort using Kaplan–Meier curves. 
 
Fig. 4. Evaluation of laryngeal function preservation in the patient cohort stratified for pT 
classification (top), pN classification (middle) and age (bottom) using Kaplan–Meier 
curves. *** = p < .001 
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Fig. 1. End point analysis (overall survival, disease specific survival, disease-free survival, locoregional 
control, and local control) of the patient cohort using Kaplan–Meier curves  
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Fig. 2. Patient cohort stratification for pT classification (left column), pN classification (middle column) and 
type of surgery (right column) using Kaplan–Meier curves. The end points considered were (from top to 
bottom) overall survival, disease-free survival, loco-regional control, and local control. * = p < .05; ** = p 
< .01; *** = p < .001  
172x164mm (600 x 600 DPI)  
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Fig.3. End point analysis of laryngeal function preservation and laryngectomy-free survival in the patient 
cohort using Kaplan–Meier curves  
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Fig. 4. Evaluation of laryngeal function preservation in the patient cohort stratified for pT classification (top), 
pN classification (middle) and age (bottom) using Kaplan–Meier curves. *** = p < .001  
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Table 1. Characteristics of the 555 patients undergoing open partial horizontal laryngectomies 
according to age, sex, Karnofsky performance status, and pathological grade 
 No. of Patients (%) 
Age, y    
Mean 59.9±9.4  
Range 16-83  
   
Sex   
Male 512/555 (92.3%)  
Female 43/555   (7.7%)  
   
Karnofsky Performance Status   
100 326/555 (58.7%)  
90 158/555 (28.5%)  
80 71/555 (12.8%)  
   
Pathological Grade Supraglottic Glottic 
pT3 34/49 (69.4%) 408/506 (80.6%) 
pT4a 15/49 (30.6%) 98/506 (19.4%) 
pN0 37/49 (75.5%) 406/454 (89.4%) 
pN1 7/49 (14.3%) 27/454   (6.0%) 
pN2 5/49 (10.2%) 21/454   (4.6%) 
   
Level VI pN+ 14/123 (11.4%)  
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Table 2:  Cause of death 
 No. of Patients (%) 
Laryngeal cancer                                 39/555   (7.0%) 
Post-operative death 3/555   (0.5%) 
II Primary 31/555   (5.6%) 
Others causes             16/555   (2.9%) 
Total deaths 89/555 (16.0%) 
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Table 3. Acute postoperative complications and late sequelae 
 No. of Patients (%) 
Acute complications  
Cervical bleeding                                       18/555 (3.2%) 
Aspiration pneumonia 16/555 (2.9%) 
Wound infection 14/555 (2.5%) 
Post-operative death             3/555 (0.5%) 
Others 10/555 (1.8%) 
  
Late sequelae  
Laryngeal soft tissue stenosis 54/555 (9.7%) 
Aspiration pneumonia 25/555 (4.5%) 
Dyspnea 6/555 (1.1%) 
 
 
 
Page 29 of 29
John Wiley & Sons, Inc.
Head & Neck
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
